Scientist and Clinician, NHS physician at the Royal Papworth Hospital Cambridge, discoverer of first effective therapies for Pulmonary Arterial Hypertension [PAH] (iv. Prostacyclin and Inhaled NO). Established the UK National Network of PAH centres. Professor, Medicine Sheffield University Medical School and Senior Principal Scientist AstraZeneca plc, Corporate Clinical Director Chiesi Farmaceutici (Italy), Architect of the first triple inhaler for asthma/COPD Trimbow®, Senior Partner TranScrip LLP, R&D Director Allergy Therapeutics plc, Vice President, and President Faculty of Pharmaceutical Medicine Royal Colleges of Medicine UK. CEO and founder of Camcon Robotics Ltd.

Gediminas “Gedi” Mainelis is a Professor in the Department of Environmental Sciences at Rutgers, the State University of New Jersey, USA. He has a Bachelor’s degree in physics from Vilnius University, Lithuania, and a Ph.D. in Environmental Health from the University of Cincinnati, Ohio, USA. His research focuses on various aspects of bioaerosol science, including sampling and analysis methods, exposure assessment, and airborne microbiomes. Over the past years, his research expanded to investigate exposures to manufactured nanoparticles and explore indoor air issues. Several of his current projects focus on COVID-19 issues. His research efforts have resulted in more than 110 peer-reviewed publications, book chapters, and several patents. In addition, multiple papers from his group have been included in the most downloaded article lists of various peer-reviewed journals. Dr. Mainelis has served as Chair of the Bioaerosols and Health-Related Aerosol working groups of the American Association for Aerosol Research (AAAR). He is currently an editor (associate) of the Aerosol and Air Quality Research journal. Prof. Mainelis is a recipient of the Research Excellence Award from Rutgers University and the Lyman A. Ripperton Environmental Educator Award presented by the A&WMA.

Mitch Simpler joined JB&B, a global consulting engineering firm, in 1977 and currently serves as a partner after having served as Managing Partner from 2012- 2018. He has acted as project manager and partner-in-charge on life/health science institutions, health care facilities, high-rise office buildings, museums, residential and mixed-use buildings, as well as hotels. Simpler’s list of notable projects in the life science sector spans the past 45 years, including premier laboratory facilities and research centers in New York City, such as the Jerome L. Greene Science Center at the Columbia University Manhattanville campus, The East River Science Park in New York, the New York Genome Center, Mount Sinai’s Hess Center for Science and Medicine, Weill Cornell Medical College’s Belfer Research Building, MSK’s David H. Koch Center for Cancer Care and Rockefeller Research Laboratories, Cornell University’s Biotechnology Building, and NYU Langone Health’s Smilow Research Building and Skirball Institute of Biomolecular Medicine. His experience extends around the world to China, with the Innovation Center at Duke Kunshan University in Kunshan and the Rohm & Haas Research Center in Shanghai. Mr. Simpler is a fellow of the American Council of Engineering Companies (ACEC) and recently served as the National Chairman of ACEC. He is also a founding member and Co-Founder of NYC Builds Bio+.

Rivkees is a Professor of the Practice of Health Services, Policy, and Practice in the School of Public Health. He served as Florida's State Surgeon General and Secretary of Health from 2019 to 2021. Before moving to Florida, he served as a professor of pediatrics with tenure at Yale University. Dr. Rivkees has had more than 35 years of continuous research funding from the National Institutes of Health. He was responsible for the safety alert on liver toxicity caused by the antithyroid drug propylthiouracil. This led to major international treatment practice changes.

Verin completed his Ph.D. at the age of 29 years from Moscow State University, Moscow, USSR, and postdoctoral studies at the University of Indiana. During his scientific carrier, he was a faculty member at Johns Hopkins and the University of Chicago. Currently, he is a Professor at the Vascular Biology Center and Pulmonary Division, School of Medicine, Medical College of Georgia, at Augusta University, Augusta, GA.   He has published more than 170 papers in reputed journals primarily in the field of pulmonary vascular endothelial barrier regulation.  He served as an Editorial board member of the American Journal of Physiology (Lung) from 2006-2011 and Editor-in-chief of the academic journal, Vessel Plus, in 2016-2022. He is currently serving as an academic editor of the British Journal of Medicine and Medical Research and Cardiology and Angiology, and an editorial board member in several other journals in the field of pulmonary/cardiovascular research such as Biomolecules, Cardiovascular Pharmacology, Journal of Multidisciplinary Pathology, Tissue Barriers, World Journal of Respirology.